DAL vs LCTX · P/E 12, rev $61.64B vs rev $9.5M
Delta Air Lines Inc (DAL) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported DAL revenue for 2024-12-31 was $61.64B. Net income was $3.46B. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
DAL currently screens at market cap $52.18B and trailing P/E 11.6. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the DAL and LCTX stock pages for the full models.
Not investment advice.